<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135226</url>
  </required_header>
  <id_info>
    <org_study_id>CTSUASCEND1</org_study_id>
    <secondary_id>EUDRACT: 2004-000991-15</secondary_id>
    <nct_id>NCT00135226</nct_id>
  </id_info>
  <brief_title>ASCEND: A Study of Cardiovascular Events iN Diabetes</brief_title>
  <official_title>A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Products</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or
      supplementation with 1 gram daily omega-3 fatty acids or placebo prevents &quot;serious vascular
      events&quot; (i.e. non-fatal heart attack, non-fatal stroke or transient ischaemic attack, or
      death from vascular causes) in patients with diabetes who are not known to have occlusive
      arterial disease and to assess the effects on serious bleeding or other adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of antiplatelet therapy (chiefly aspirin) for the secondary prevention of heart
      attacks and strokes is firmly established for many high-risk people with diagnosed arterial
      disease, and the proportional reductions in these cardiovascular events appear to be about
      one quarter, whether or not such patients have diabetes. But, most younger and middle-aged
      people with diabetes do not have manifest arterial disease - although they are still at
      significant cardiovascular risk - and yet few trials have tested aspirin in such individuals.
      As a result, there is substantial uncertainty about the role of aspirin for the prevention of
      heart attacks and strokes among apparently healthy people with diabetes, and only a small
      minority receives it.

      There is consistent evidence from observational studies of lower rates of cardiovascular
      disease (particularly cardiac and sudden death) in people with higher intakes, or higher
      blood levels, of fish oils (omega-3 fatty acids). Trials in people who have survived a heart
      attack have shown modest, but potentially worthwhile, reductions in coronary events. There
      have been, however, no large-scale trials of the use of fish oils for the prevention of
      vascular events in people without diagnosed arterial disease.

      If ASCEND can reliably demonstrate that aspirin and/or fish oils safely reduce the risk of
      cardiovascular events and deaths in people with diabetes who do not have pre-existing
      arterial disease, then this would be relevant to some tens of millions of people world-wide
      (who are currently not receiving such therapy) and might save tens of thousands of lives each
      year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combination of non-fatal myocardial infarction, non-fatal stroke or transient ischaemic attack, or vascular death, excluding confirmed cerebral haemorrhage</measure>
    <time_frame>median 7.5 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious vascular event in various prognostic subgroups</measure>
    <time_frame>median 7.5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral haemorrhage</measure>
    <time_frame>median 7.5 years follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15480</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aspirin + Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 100mg of aspirin once daily and 1g of omega-3-Ethyl Esters once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin + Placebo Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 100mg of aspirin once daily and placebo omega-3-Ethyl Esters once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Aspirin + Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo aspirin once daily and 1 g of omega-3-Ethyl Esters once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Aspirin + Placebo Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo aspirin once daily and placebo omega-3-Ethyl Esters once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <arm_group_label>Aspirin + Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_label>Aspirin + Placebo Omega-3-Ethyl Esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3-acid Ethyl Esters</intervention_name>
    <arm_group_label>Aspirin + Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_label>Placebo Aspirin + Omega-3-Ethyl Esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Aspirin</intervention_name>
    <arm_group_label>Placebo Aspirin + Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_label>Placebo Aspirin + Placebo Omega-3-Ethyl Esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo omega-3-Ethyl Esters</intervention_name>
    <arm_group_label>Aspirin + Placebo Omega-3-Ethyl Esters</arm_group_label>
    <arm_group_label>Placebo Aspirin + Placebo Omega-3-Ethyl Esters</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females with type 1 or type 2 diabetes mellitus.

          -  Aged â‰¥ 40 years.

          -  No previous history of vascular disease.

          -  No clear contra-indication to aspirin.

          -  No other predominant life-threatening medical problem.

        Exclusion Criteria:

          -  Definite history of myocardial infarction, stroke or arterial revascularisation
             procedure.

          -  Currently prescribed aspirin, warfarin or any other blood thinning medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane M Armitage, BSc, MBBS, MRCP, FFPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Service Unit, University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Service Unit, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ctsu.ox.ac.uk/ascend</url>
    <description>Click here for more information about ASCEND : A Study of Cardiovascular Events iN Diabetes</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Primary prevention</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

